View Post

Relationship of Radiation Dose to Efficacy of Radioembolization of Liver Metastasis from Breast Cancer

In Clinical Trials by Barbara Jacoby

From: mdlinx.com Highlights Higher radiation dose to breast cancer liver metastases during radioembolization is associated with objective response. A dose threshold to tumor of 79.5 Gy is proposed to achieve objective response. Longer survival is associated with objective response. Shorter survival is associated with worse pre-radioembolization liver function, bilobar disease, and radioembolization-associated liver impairment. Accurate pre-treatment dosimetry may help optimize response …

View Post

Strata Oncology Announces Personalized Recurrence Monitoring Trial

In Clinical Trials by Barbara Jacoby

From: PR Newswire Study to Evaluate Strata’s Ability to Detect Tumor Recurrence using Liquid Biopsy and Monitor Treatment Effectiveness for Patients with Early-Stage Solid Tumors Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced plans to begin enrolling the Sentinel Trial in the first half of 2021. Sentinel is a prospective, observational study designed …

View Post

DarwinHealth Scientists Publish Foundational Research Identifying Regulatory Mechanisms Controlling Cancer Cell States and Drug Response

In Clinical Trials by Barbara Jacoby

From: PR Newswire DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the January 11, 2021 online publication in Cell of a landmark paper, “A Modular Master Regulator Landscape Controls Cancer Transcriptional Identity,”1,2 in which scientists from Columbia University and DarwinHealth apply the VIPER (Virtual Inference of Protein activity by Enriched Regulon) analysis algorithm to identify recurrent regulatory networks—”tumor …

View Post

Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers

In Clinical Trials by Barbara Jacoby

By: DocWire News Featured Reading From: docwirenews.com ABSTRACT BACKGROUND: Most minorities receive cancer care at minority-serving hospitals (MSHs) that have been associated with disparate treatment between Black and White patients. OBJECTIVE: Our aim was to examine the uptake of clinical trials that have changed axillary management in breast cancer patients at MSH and non-MSH cancer centers. METHODS: The National Cancer …

View Post

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment

In Clinical Trials by Barbara Jacoby

From: dovepress.com Objective: This study aimed to investigate the influence of immunohistochemical (IHC) biomarkers in the response to neoadjuvant chemotherapy (NACT) and survival outcomes in the subset of locally advanced triple-negative breast cancer (TNBC). Materials and Methods: The epidermal growth factor receptor (EGFR), androgen receptor (AR), cytokeratins (CK5/6, CK14 and CK17), Ki67 and p53 immunohistochemistry were evaluated on 171 cases …

View Post

RadNet’s DeepHealth Artificial Intelligence Subsidiary Demonstrates Earlier Breast Cancer Detection in New Study

In Clinical Trials by Barbara Jacoby

Source: RadNet, Inc. From: globenewswire.com RadNet, Inc. (NASDAQ: RDNT) today reported that its DeepHealth subsidiary, a leading developer of artificial intelligence (AI) for mammography interpretation, published results of its novel AI algorithms in Nature Medicine, illustrating an ability to detect breast cancer a year or more earlier than current practice. DeepHealth compared its AI to five full-time, breast-fellowship-trained expert radiologists …

View Post

Could Amgen’s Xgeva boost immunotherapy in breast cancer?

In Clinical Trials by Barbara Jacoby

By: Arlene Weintraub From: fiercebiotech.com Amgen’s osteoporosis drug denosumab is approved as Xgeva for the prevention and treatment of some bone metastases in cancer. But could the drug’s mechanism of action help breast cancer patients respond to immunotherapy drugs that typically don’t work well in those tumors? That was the premise behind a new study led by the Bellvitge Institute …

View Post

What Is Clinical Utility in a Tumor Biomarker Test? Former ASCO President Knows It When He Sees It

In Clinical Trials by Barbara Jacoby

By: Mary Caffrey From: .ajmc.com Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility. A former president of the American Society of Clinical Oncology (ASCO) has provided a “pragmatic clinical guide” for fellow oncologists in deciding when to use tumor biomarker tests (TBTs) across an array of cancers, recognizing that the standard of “clinical …

View Post

Practicing Outside the Pharma Box in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Dawn Fallik From: onclive.com When Martine Piccart, MD, PhD, was a child, she sometimes watched her father, a gynecologist, talk to his patients. She remembers his respect for them and their families and the way he communicated, focusing on the positive but not shying away from delivering bad news. “He always took the time to explain in detail not …

View Post

Gut microbe may promote breast cancers

In Clinical Trials by Barbara Jacoby

Source: Johns Hopkins Medicine From: eurekalert.org Short-term exposure to B. fragilis toxin leaves lasting impression in cells, increasing the risk for cancer A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns …